Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23657327 | 0.84 | HRH4 (0.48) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL25493328 | 0.81 | HRH4 (0.70) | HTR3AHRH4 | |
| SCHEMBL3998628 | 0.80 | TERT (0.45) | HRH4KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4120084 | 0.78 | TERT (0.47) | HRH4KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8318081 | 0.78 | BCL2A1 (0.59) | HTR3AKDM4ERAB9ASMN1; SMN2MEN1 | |
| SCHEMBL25497715 | 0.77 | HRH4 (0.48) | HRH4KDM4E | |
| SCHEMBL1849544 | 0.77 | HRH4 (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL1588132 | 0.77 | HRH4 (0.52) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL13173967 | 0.77 | KDM4E (0.53) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL26604077 | 0.77 | HRH4 (0.50) | HTR3AHRH4KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805142-A4 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS INC (US) | 2009-06-10 | — | — | EP | claimed |
| EP-1805142-A2 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2006034474-A2 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20100168077-A1 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-01 | — | — | US | disclosed |
| EP-2144877-A1 | NOVEL PYRIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS THEREOF | UCB Pharma, S.A. (BE) | 2010-01-20 | — | — | EP | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2008122378-A1 | NOVEL PYRIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS THEREOF | UCB PHARMA, S.A. (BE) | 2008-10-16 | — | — | WO | disclosed |
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | LDLR, LRP6, PLPBP | HTR3A 4057/4885HTR3E 3985/4885HTR3B 4021/4885 |
| US-20100168077-A1 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof | CYP4B1, CYP3A4, CYP2C19 | HTR3A 273/4885HTR3E 330/4885HTR3B 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.